These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11599654)

  • 1. Clinical pharmacology of thalidomide.
    Eriksson T; Björkman S; Höglund P
    Eur J Clin Pharmacol; 2001 Aug; 57(5):365-76. PubMed ID: 11599654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.
    Eriksson T; Björkman S; Roth B; Höglund P
    J Pharm Pharmacol; 2000 Jul; 52(7):807-17. PubMed ID: 10933131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide.
    Eriksson T; Björkman S; Roth B; Fyge A; Höglund P
    Chirality; 1995; 7(1):44-52. PubMed ID: 7702998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics of thalidomide.
    Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL
    Clin Pharmacokinet; 2004; 43(5):311-27. PubMed ID: 15080764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey.
    Schmahl HJ; Nau H; Neubert D
    Arch Toxicol; 1988; 62(2-3):200-4. PubMed ID: 3143339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis.
    Eriksson T; Björkman S; Roth B; Fyge A; Höglund P
    Chirality; 1998; 10(3):223-8. PubMed ID: 9499573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method for determination of both thalidomide enantiomers using HPLC systems.
    Sembongi K; Tanaka M; Sakurada K; Kobayashi M; Itagaki S; Hirano T; Iseki K
    Biol Pharm Bull; 2008 Mar; 31(3):497-500. PubMed ID: 18310917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
    Breitkreutz I; Anderson KC
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
    Murphy S; Boyle FM; Davey RA; Gu XQ; Mather LE
    J Pharm Pharmacol; 2007 Jan; 59(1):105-14. PubMed ID: 17227627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
    Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K
    Chirality; 1996; 8(5):390-6. PubMed ID: 8900028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.
    Ginsburg PM; Dassopoulos T; Ehrenpreis ED
    Ann Med; 2001 Nov; 33(8):516-25. PubMed ID: 11730158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide: a remarkable comeback.
    Jacobson JM
    Expert Opin Pharmacother; 2000 May; 1(4):849-63. PubMed ID: 11249521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide: current and potential clinical applications.
    Calabrese L; Fleischer AB
    Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug].
    Borges Lde G; Frõehlich PE
    Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study of the sedative effects of the thalidomide enantiomers in humans.
    Höglund P; Eriksson T; Björkman S
    J Pharmacokinet Biopharm; 1998 Aug; 26(4):363-83. PubMed ID: 10214558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Model to Assess the Impact of Disease State on Thalidomide Pharmacokinetics.
    Gaudy A; Hwang R; Palmisano M; Chen N
    J Clin Pharmacol; 2020 Jan; 60(1):67-74. PubMed ID: 31392755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.
    Jacques V; Czarnik AW; Judge TM; Van der Ploeg LH; DeWitt SH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(12):E1471-9. PubMed ID: 25775521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides.
    Yamamoto T; Shibata N; Sukeguchi D; Takashima M; Nakamura S; Toru T; Matsunaga N; Hara H; Tanaka M; Obata T; Sasaki T
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3973-6. PubMed ID: 19297157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling and simulation to probe the pharmacokinetic disposition of pomalidomide R- and S-enantiomers.
    Li Y; Zhou S; Hoffmann M; Kumar G; Palmisano M
    J Pharmacol Exp Ther; 2014 Aug; 350(2):265-72. PubMed ID: 24833703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative oncology: thalidomide.
    Prommer EE
    Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.